Podcasts about neurology aan

Emma Wille and Summer Colling discuss the 2025 American Academy of Neurology (AAN) conference with CNS and I&I analysts Wen-Yu Huang, Joseph Jacob and Istafa Armughan.

Welcome to season 6 of Hope for the Agora Podcast.Karen Kleine Deters shares her story of journeying with FND -- Functional Neurologic Disorder.Functional neurologic disorder (FND) refers to a neurological condition caused by changes in how brain networks work, rather than changes in the structure of the brain itself, as seen in many other neurological disorders. Physical symptoms of FND are genuine but cannot be explained by changes in the brain structure. The exact cause of FND is unknown.Resources:National Institute of Neurological Disorders and Stroke (NINDS). Functional Neurological Disorder Information Page. https://www.ninds.nih.gov/health-information/disorders/functional-neurological-disorderStone, J., Carson, A., & Sharpe, M. (2005). Functional symptoms and signs in neurology: assessment and diagnosis. *Journal of Neurology, Neurosurgery & Psychiatry, 76*(Suppl I), i2–i12. https://jnnp.bmj.com/content/76/suppl_1/i2Support & Awareness OrganizationsFND Hope International – https://fndhope.orgThe Functional Neurological Disorder Society (FNDS) – https://www.fndsociety.orgMayo Clinic: Functional Neurological Disorder – https://www.mayoclinic.org/diseases-conditions/conversion-disorder/symptoms-causes/syc-20355197Podscasts and storiesNeurology Podcast by the American Academy of Neurology (AAN) – https://www.aan.com/podcastFND Portal Podcast (FND Hope International) – https://fndhope.org/fnd-portal-podcast

Join Wade Cooper, DO and Jessica Ailani, MD as they share highlights from the 2024 American Academy of Neurology (AAN) annual meeting in Denver, Colorado. In this first episode of a three‑part series, they discuss acute medication overuse in people with migraine, strategies to help patients to avoid overuse, and layering migraine therapies, among other topics.

Send us a textWelcome back to Headfirst: A Concussion Podcast. Today, we're thrilled to have the esteemed Dr. Nitin Sethi.Dr. Sethi is a former boxing and UFC ringside neurologist and a board-certified neurologist specializing in epilepsy and clinical neurophysiology. Dr Sethi holds additional certifications from the American Board of Psychiatry and Neurology in epilepsy and sleep medicine, as well as from the American College of Sports Medicine and the Association of Ringside Physicians as a Certified Ringside Physician. In addition to his numerous publications and his book, Neurologist at Ringside, Dr. Sethi has received several notable appointments and awards, including: The Certificate of Congressional Recognition "Heroes Humanity Award" from U.S. Congresswoman Grace F. Napolitano, awarded on behalf of the World Boxing Council (WBC) for his service to communities in need. Recognition as a Leading Physician of the World and Top Neurologist in New York by The International Association of HealthCare Professionals in 2012. Appointment as Vice Chairman of the Sports Neurology Section of the American Academy of Neurology (AAN) from 2022 to 2024. Serving as an Unaffiliated and Independent Neurotrauma Consultant for the NFL from 2013 to the present. Being a Ringside Panel Physician for the New York State Athletic Commission since 2012.  -       Introduction  -       What Is a Concussion? (6:45)-       Neurological Assessment Athletes Pre and Post-Fight (9:19)-       Mentality of a Boxer/Fighter (19:01)-       How Too Change Sporting Culture? (27:38)-       UFC 244 Welterweight Main Card Jorge Masvidal vs Nate Diaz and the Fallout (32:00)-       Positives of Combat Sports (45:32) Book: Neurologist at Ringside – Amazon.com Journal Articles-       To be or not to be ringside? Ethical issues pertaining to combat sports medicine: https://www.tandfonline.com/doi/full/10.1080/00913847.2022.2043129-       Neuroimaging in professional combat sports: consensus statement from the association of ringside physicians: https://www.tandfonline.com/doi/full/10.1080/00913847.2022.2083922-       Care of The Older Fighter: Position Statement of the Association of Ringside Physicians: https://www.tandfonline.com/doi/full/10.1080/00913847.2024.2344227    Subscribe, review and share for new episodes which will drop fortnightlySocial media:Twitter: @first concussionFacebook: Headfirst: A concussion podcastInstagram: Headfirst_ Concussion  Email: headfirstconcussion@gmail.com

On this special episode Dr. Correa speaks to David A. Evans, MBA, CEO of Texas Neurology and Natalia S. Rost, MD, MPH, FAAN, FAHA, chief of the stroke division at Massachusetts General Hospital and president-elect of the American Academy of Neurology (AAN). David and Dr. Rost speak about the AAN's newly published position statement on brain health including the organization's definition of brain health and vision for the future of brain health for all. Dr. Rost and David also discuss their experiences with neurologic conditions and share how they incorporate brain healthy activities into their daily lives.   Additional Resources  Neurology®: The AAN Brain Health Platform and Position Statement   AAN's Brain Health Initiative   Information on Stroke  We want to hear from you!  Have a question or want to hear a topic featured on the Brain & Life Podcast?  Record a voicemail at 612-928-6206  Email us at BLpodcast@brainandlife.org  Social Media:   Guest: Dr. Natalia Rost @nsanar (Twitter & Instagram); Mr. David Evans @davidevanstx (Twitter)  Host: Dr. Daniel Correa @neurodrcorrea 

Lyme disease is the most common tick-borne disease in the US that can present in three different stages. Diagnosis is through a combination of a thorough history, review of systems, physical exam, as well as a two-tier serologic testing. Former Pediatric resident, Dr. James Davis, joins Associate Professor of Pediatrics, Dr. Susan Goldberg, to discuss the evaluation and management of Lyme Disease in the pediatric population. After listening to this podcast, learners should be able to: Recognize common presenting signs and symptoms of Early Localized, Early Disseminated, and Late Lyme disease from a patient history and physical examination Determine whether a patient meets clinical diagnostic criteria and, if not, which lab tests are appropriate for diagnosis of Lyme disease Appropriately prescribe the correct antibiotic choice and duration for patients, depending on variation of Lyme disease and accompanying symptoms Accurately and effectively instruct patients in prevention strategies for tick bites and Lyme disease Special thanks to Dr. Ingrid Camelo, Dr. Rebecca Yang and Dr. Jacob Eichenberger who peer reviewed today's episode. FREE CME Credit (requires free sign-up): https://mcg.cloud-cme.com/course/courseoverview?P=0&EID=11411  References: Rodino KG, Theel ES, Pritt BS. Tick-Borne Diseases in the United States. Clin Chem. 2020 Apr 1;66(4):537-548. doi: 10.1093/clinchem/hvaa040. PMID: 32232463. Lantos PM, Rumbaugh J, Bockenstedt LK, Falck-Ytter YT, Aguero-Rosenfeld ME, Auwaerter PG, Baldwin K, Bannuru RR, Belani KK, Bowie WR, Branda JA, Clifford DB, DiMario FJ, Halperin JJ, Krause PJ, Lavergne V, Liang MH, Meissner HC, Nigrovic LE, Nocton JJJ, Osani MC, Pruitt AA, Rips J, Rosenfeld LE, Savoy ML, Sood SK, Steere AC, Strle F, Sundel R, Tsao J, Vaysbrot EE, Wormser GP, Zemel LS. Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease. Clin Infect Dis. 2021 Jan 23;72(1):e1-e48. doi: 10.1093/cid/ciaa1215. PMID: 33417672. Eddens T, Kaplan DJ, Anderson AJM, Nowalk AJ, Campfield BT. Insights From the Geographic Spread of the Lyme Disease Epidemic. Clin Infect Dis. 2019 Jan 18;68(3):426-434. doi: 10.1093/cid/ciy510. PMID: 29920580; PMCID: PMC6336907. Sundheim KM, Levas MN, Balamuth F, Thompson AD, Neville DN, Garro AC, Kharbanda AB, Monuteaux MC, Nigrovic LE. Seasonality of Acute Lyme Disease in Children. Trop Med Infect Dis. 2021 Nov 9;6(4):196. doi: 10.3390/tropicalmed6040196. PMID: 34842846; PMCID: PMC8628899. 2021. "Lyme Disease (Lyme Borreliosis, Borrelia burgdorferi sensu lato Infection)", Red Book: 2021–2024 Report of the Committee on Infectious Diseases, Committee on Infectious Diseases, American Academy of Pediatrics, David W. Kimberlin, MD, FAAP, Elizabeth D. Barnett, MD, FAAP, Ruth Lynfield, MD, FAAP, Mark H. Sawyer, MD, FAAP Bax CE, Clark AK, Oboite M, Treat JR. A case of disseminated Lyme disease in a child with skin of color. Pediatr Dermatol. 2021 Nov;38 Suppl 2:140-141. doi: 10.1111/pde.14770. Epub 2021 Sep 13. PMID: 34515362. Lipsett SC, Nigrovic LE. Diagnosis of Lyme disease in the pediatric acute care setting. Curr Opin Pediatr. 2016 Jun;28(3):287-93. doi: 10.1097/MOP.0000000000000339. PMID: 27138805. Shapiro ED. Borrelia burgdorferi (Lyme disease). Pediatr Rev. 2014 Dec;35(12):500-9. doi: 10.1542/pir.35-12-500. PMID: 25452659; PMCID: PMC5029759. Meissner HC, Steere AC. Management of Pediatric Lyme Disease: Updates From 2020 Lyme Guidelines. Pediatrics. 2022 Mar 1;149(3):e2021054980. doi: 10.1542/peds.2021-054980. PMID: 35229121. Bolourchi M, Silver ES, Liberman L. Advanced Heart Block in Children with Lyme Disease. Pediatr Cardiol. 2019 Mar;40(3):513-517. doi: 10.1007/s00246-018-2003-8. Epub 2018 Oct 31. PMID: 30377753. Chason ME, Monaghan M, Wang J, Cheng Y, DeBiasi RL. Symptom Resolution in Pediatric Patients With Lyme Disease. J Pediatric Infect Dis Soc. 2019 May 11;8(2):170-173. doi: 10.1093/jpids/piy067. PMID: 30060012. 2021. "Prevention of Mosquitoborne and Tickborne Infection", Red Book: 2021–2024 Report of the Committee on Infectious Diseases, Committee on Infectious Diseases, American Academy of Pediatrics, David W. Kimberlin, MD, FAAP, Elizabeth D. Barnett, MD, FAAP, Ruth Lynfield, MD, FAAP, Mark H. Sawyer, MD, FAAP Centers for Disease Control and Prevention. Preventing Tick Bites on People [Internet]. Atlanta, GA: Centers for Disease Control and Prevention; Sept 2019 [cited 2022 March 30]. Available from: https://www.cdc.gov/lyme/prev/on_people.html

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Jennifer Majersik, MD, MS, chief, division of vascular neurology, and professor of neurology, University of Utah, who along with 9 other colleagues, authored a report from the American Academy of Neurology (AAN) 2019 Transforming Leaders Program on the ongoing shortage of physicians in neurology. She offered her perspective on the challenge and how it can be addressed from an individual and institutional level. Episode Breakdown: 3:40 – Overview of the shortage in neurology 5:00 – Attracting new medical students to neurology 7:05 – The role of AAN and medical organizations 9:35 – The role of the individual neurologist 11:50 – The increase in fellowship training in neurology 14:00 – The impact on patient care Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com. REFERENCES 1. Majersik JJ, Ahmed A, Chen IA, et al. A shortage of neurologists – we must act now: A report from the AAN 2019 transforming leaders program. Neurology. Published online April 30, 2021. doi:10.1212/WNL.0000000000012111 2. AAMC Report Reinforces Mounting Physician Shortage. News release. AAMC. June 11, 2021. Accessed December 30, 2021. https://www.aamc.org/news-insights/press-releases/aamc-report-reinforces-mounting-physician-shortage

In this episode, Akanksha shares how a patient under her care became the inspiration for her work in palliative medicine. She shares her perspective on the need for doctors to have "the conversation" with patients facing a terminal illness and their families.Akanksha Sharma, MD, is board-certified in neurology, neuro-oncology, and palliative medicine. She is experienced in treating primary/metastatic brain tumors, neurological complications of cancer, and disease-related burden and symptoms.Her clinical and research interests lie in helping patients maximize their time and quality of life. She aims to align treatment with patient goals and provide holistic care that includes careful symptom assessment and management and support for the patient's loved ones. Dr. Sharma brings a unique perspective to neuro-oncology care in this area with her clinical experience combining neuro-oncology and palliative care. Her research focuses on understanding and improving quality of life, how we best manage symptoms, the importance of prognostication, and caregiver support. She partners with her patients and their families to develop holistic care plans that consider both mind and body health and the patient's loved ones.Dr. Sharma completed Neurology training at the University of Washington.She then completed a two-year research/clinical Neuro-oncology fellowship at the Mayo Clinic in Arizona, followed by a Hospice and Palliative Medicine fellowship at the University of Washington.She is an active member of the Society for Neuro-oncology (SNO) (for whom she serves on the Women & Diversity Committee), the American Academy of Neurology (AAN), and the American Association of Hospice & Palliative Medicine (AAHPM).Support the show (https://healgrief.org/donations/)

This fact sheet is provided to help you understand the current evidence for diagnosing and managing facioscapulohumeral muscular dystrophy (FSHD). The American Academy of Neurology (AAN) is the world’s largest association of neurologists and neuroscience professionals. Neurologists are doctors who identify and treat diseases of the brain and nervous system, including neuromuscular disorders. The American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) is an association of neurologists, doctors of physical medicine and rehabilitation (PMR), and other health care professionals. PMR doctors specialize in rehabilitation. The AAN is dedicated to promoting the highest quality patient-centered neurologic care. The AANEM is dedicated to advancing the care of patients with muscle and nerve disorders. Experts from the AAN and AANEM carefully reviewed the available scientific studies on diagnosing and managing FSHD. The following information is based on evidence from those studies and other key information. The information summarizes the main findings of the 2015 AAN and AANEM guideline on FSHD.

Lyme disease is a complex infection and post infection syndrome can lead to serious outcomes, including death. A new guideline was developed for the diagnosis and treatment of this infection. Spoon! This episode is accredited for CPE. Subscribe at CEimpact ( https://www.ceimpact.com/pharmacist ) and claim your CE today! Reference: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease. Clinical Infectious Diseases, November 30, 2020. https://doi.org/10.1093/cid/ciaa1215. Accessed at https://www.idsociety.org/practice-guideline/lyme-disease/  CPE details for GameChangers Podcast February 2021 Learning Objective: Discuss treatment for different forms of lyme disease infections depending on the severity of symptoms 0107-0000-21-XXX-H01-P 0.2 CEU/2.0 Hrs (Knowledge) Initial Release Date: 02/23/21 Expiration Date: 02/23/24 Additional CPE information is located at https://www.ceimpact.com/podcast  See omnystudio.com/listener for privacy information. Learn more about your ad choices. Visit megaphone.fm/adchoices

Lyme disease is a complex infection and post infection syndrome can lead to serious outcomes, including death. A new guideline was developed for the diagnosis and treatment of this infection. Spoon! This episode is accredited for CPE. Subscribe at CEimpact ( https://www.ceimpact.com/pharmacist ) and claim your CE today! Reference: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease. Clinical Infectious Diseases, November 30, 2020. https://doi.org/10.1093/cid/ciaa1215. Accessed at https://www.idsociety.org/practice-guideline/lyme-disease/  CPE details for GameChangers Podcast February 2021 Learning Objective: Discuss treatment for different forms of lyme disease infections depending on the severity of symptoms 0107-0000-21-XXX-H01-P 0.2 CEU/2.0 Hrs (Knowledge) Initial Release Date: 02/23/21 Expiration Date: 02/23/24 Additional CPE information is located at https://www.ceimpact.com/podcast  See omnystudio.com/listener for privacy information.

Lyme disease is a complex infection and post infection syndrome can lead to serious outcomes, including death. A new guideline was developed for the diagnosis and treatment of this infection. Spoon!This episode is accredited for CPE. Subscribe at CEimpact( https://www.ceimpact.com/pharmacist ) and claim your CE today!Reference: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease. Clinical Infectious Diseases, November 30, 2020. https://doi.org/10.1093/cid/ciaa1215. Accessed athttps://www.idsociety.org/practice-guideline/lyme-disease/ CPE details for GameChangers Podcast February 2021Learning Objective: Discuss treatment for different forms of lyme disease infections depending on the severity of symptoms0107-0000-21-XXX-H01-P0.2 CEU/2.0 Hrs (Knowledge)Initial Release Date: 02/23/21Expiration Date: 02/23/24Additional CPE information is located at https://www.ceimpact.com/podcast See omnystudio.com/listener for privacy information.

Lyme disease is a complex infection and post infection syndrome can lead to serious outcomes, including death. A new guideline was developed for the diagnosis and treatment of this infection. Spoon! This episode is accredited for CPE. Subscribe at CEimpact ( https://www.ceimpact.com/pharmacist ) and claim your CE today! Reference: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease. Clinical Infectious Diseases, November 30, 2020. https://doi.org/10.1093/cid/ciaa1215. Accessed at https://www.idsociety.org/practice-guideline/lyme-disease/  CPE details for GameChangers Podcast February 2021 Learning Objective: Discuss treatment for different forms of lyme disease infections depending on the severity of symptoms 0107-0000-21-XXX-H01-P 0.2 CEU/2.0 Hrs (Knowledge) Initial Release Date: 02/23/21 Expiration Date: 02/23/24 Additional CPE information is located at https://www.ceimpact.com/podcast  See omnystudio.com/listener for privacy information.

What is Mitochondrial Myopathy? my·op·a·thy mīˈäpəTHē/ The word “myopathy” means disease of the muscle tissue. As the term implies, mitochondrial myopathy (MM) is a neuromuscular disease caused by damage to the mitochondria. Many patients with mitochondrial disease have a mitochondrial myopathy, either as their sole diagnosis or as an additional, descriptive co-diagnosis as part of their mitochondrial disorder. Mitochondrial myopathy may be present in adults and children, and may occur with or without a genetic mitochondrial disease diagnosis. Further, several clinical trials are currently examining the impact of various therapies or potential treatments for people with mitochondrial myopathy. Join us this month on Friday, November 20th at 12 pm EST with Dr. Bruce Cohen, Director of Pediatric Neurology and then the Director of the NeuroDevelopmental Science Center at Akron Children’s Hospital. Dr. Cohen is well-known and highly respected as an expert author, speaker, clinician and research investigator in mitochondrial disorders. Topics for this important discussion include: What is mitochondrial myopathy? How is it diagnosed? Are there treatments for mitochondrial myopathy? Other management strategies? What are the most common symptoms of mitochondrial myopathy? Who typically is diagnosed with mitochondrial myopathy? About The Speaker Dr. Bruce H. Cohen attended college at Washington University in St. Louis and a BA in chemistry, graduating summa cum laude in 1978. He received his medical degree from the Albert Einstein College of Medicine in Bronx, N.Y. in 1982 and went on to his pediatric residency at the Children’s Hospital of Philadelphia, followed by a residency in neurology at Columbia Presbyterian Medical Center in New York. He then obtained a two-year American Cancer Society fellowship in neuro-oncology at the Children’s Hospital of Philadelphia. In 1989 Dr. Cohen joined the Cleveland Clinic’s department of Neurology, and served as chief of Pediatric Neurology from 1999-2002, with joint appointments in the Clinic’s Taussig Cancer Center, the Eepartment of Neurosurgery and the department of Pediatrics. In 2011, he joined Akron Children’s Hospital in Akron, Ohio, as Director of Pediatric Neurology and then the Director of the NeuroDevelopmental Science Center. He serves in many leadership roles within Akron Children’s Hospital. His specialty interests include adult and pediatric neuro-oncology, mitochondrial medicine, neurofibromatosis, neurometabolic diseases and pediatric neurology. He has served on a number of committees for the Children’s Oncology Group, the American Academy of Neurology (AAN), the Child Neurology Society. He currently serves as chairman of the Coding Subcommittee within the Medical Economics and Management Committee of the AAN, and Secretary-Treasurer of the CNS. His past leadership positions include Chairman of the Pediatric Section of the AAN, Chairman of the Practice Com

Maurice Ohayon, MD, PhD, Professor of Psychiatry and Behavioral Sciences atStanford University summarizes key research on narcolepsy presented at the American Academy of Neurology (AAN) 2020 annual meeting.To obtain CME credit, go to https://checkrare.com/learning/p-aan2020-narcolepsy-abstract-highlights-from-aan-2020/

Michael Levy, MD, PhD, Associate Professor, Harvard Medical School summarizes key research on neuromyelitis optica spectrum disorder (NMOSD) presented at the American Academy of Neurology (AAN) 2020 annual meeting. To obtain CME credit, go to https://checkrare.com/learning/p-aan2020-nmosd-abstract-highlights-from-aan-2020/

Dr. Jason Crowell discusses novel approaches to pain management, one of the many programs at the upcoming AAN Fall Conference. The AAN Fall Conference will be held on November 6-7 (virtually). Click here for more information: https://www.aan.com/conferences-community/regional-conferences/fall-conference/  

Dr. Natalia Rost shares information on the AAN's Science Highlights Program. Show References: 2020 AAN Science Highlights Virtual Platform: https://cslide-us.ctimeetingtech.com/aan2020/attendee/home

In part 2 of this 2-part series, Dr. James Stevens, president of the American Academy of Neurology [AAN], shares the advocacy actions that the AAN has taken to support neurologists during the COVID-19 pandemic. You can find additional COVID-19 resources from the AAN here: https://www.aan.com/tools-and-resources/covid-19-neurology-resource-center/

In part 1 of this 2-part series, Dr. James Stevens, president of the American Academy of Neurology [AAN], shares the advocacy actions that the AAN has taken to support neurologists during the COVID-19 pandemic. You can find additional COVID-19 resources from the AAN here: https://www.aan.com/tools-and-resources/covid-19-neurology-resource-center/

It’s 2020, and for the first time in its 72-year history, the American Academy of Neurology has cancelled its annual meeting because of the COVID-19 pandemic. But that does not mean we (BrainWaves producers, not the AAN) can’t provide a few major updates to advances in neurology and neurotherapeutics! This week on the program, Jim Siegler is joined by Dr. Sammita Satyanarayan (Stanford) on a whirlwind tour of some of the latest advances in neurology from this past year. Enjoy! ** IF YOU’RE TAKING YOUR NEUROLOGY BOARDS THIS SUMMER, CHECK OUT THE PENN NEUROLOGY BOARD REVIEW COURSE AT https://upenn.cloud-cme.com/default.aspx?P=5&EID=65373. AND FOR A DISCOUNTED RATE ON THE ONLINE OR STREAMING RESOURCES, USE PROMO CODE ‘WAVES2020’. ** DISCLAIMER: BrainWaves: A Neurology Podcast is not a product of the American Academy of Neurology (AAN) or its affiliates. Any content discussed on the program does not reflect the opinions of the AAN or its leadership nor does it contain any copyrighted material by the AAN or its affiliates. This program is neither published in collaboration with the AAN nor is it intended to plagiarize any content or programming of the AAN or its affiliates. The opinions discussed in this program are those of the producers and are not reflective of their employers or affiliates. This episode was produced by Sammita Satyanarayan and James E. Siegler. Music courtesy of E’s Jammy Jams, Lee Roosevere, Rui, and Steve Combs. The opening theme was composed by Jimothy Dalton. Sound effects by Mike Koenig and Daniel Simion. Unless otherwise mentioned in the podcast, no competing financial interests exist in the content of this episode. BrainWaves' podcasts and online content are intended for medical education only and should not be used for clinical decision making. Be sure to follow us on Twitter @brainwavesaudio for the latest updates to the podcast. REFERENCES Dodick D, Lipton RB, Martin V, Papademetriou V, Rosamond W, MaassenVanDenBrink A, et al. Consensus statement: Cardiovascular safety profile of triptans (5-ht agonists) in the acute treatment of migraine. Headache. 2004;44:414-425 Hall GC, Brown MM, Mo J, MacRae KD. Triptans in migraine: The risks of stroke, cardiovascular disease, and death in practice. Neurology. 2004;62:563-568 Campbell BCV, Mitchell PJ, Churilov L, Yassi N, Kleinig TJ, Dowling RJ, et al. Tenecteplase versus alteplase before thrombectomy for ischemic stroke. The New England journal of medicine. 2018;378:1573-1582 Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB, et al. Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study. Neurology. 2018;91:e2222-e2232 Cortese I, Muranski P, Enose-Akahata Y, Ha SK, Smith B, Monaco M, et al. Pembrolizumab treatment for progressive multifocal leukoencephalopathy. The New England journal of medicine. 2019;380:1597-1605 Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019;142:1894-1904 Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, Wild EJ, Saft C, Barker RA, et al. Targeting huntingtin expression in patients with huntington's disease. The New England journal of medicine. 2019;380:2307-2316 Campbell BCV, Mitchell PJ, Churilov L, Yassi N, Kleinig TJ, Dowling RJ, et al. Effect of intravenous tenecteplase dose on cerebral reperfusion before thrombectomy in patients with large vessel occlusion ischemic stroke: The extend-ia tnk part 2 randomized clinical trial. JAMA : the journal of the American Medical Association. 2020. Epub ahead of print.

In this episode, we explore disease modifying therapies (DMT’s) a little more as well as discuss reliable resources of information such as the National Multiple Sclerosis Society (NMSS) and the American Academy of Neurology (AAN). We also discuss an article, “New MS treatment guidelines” from the NMSS’ quarterly publication, Momentum. The guidelines from the AAN referenced in the article and podcast, are under the Clinician Summary box. And finally, there is a list of medications provided by the NMSS to "Modify the disease course" that is a great reference as well.

1. Featured Article: Quality improvement in neurology: Epilepsy Quality Measurement Set 2017 Update2. What’s Trending: Using artificial intelligence in neurological diagnosisDr. Jeff Ratliff talks with Dr. Anup Patel about his paper on the 2017 epilepsy quality measurement set update. In the second part of the podcast, Dr. Andy Southerland focuses his interview with Dr. Eric Oermann on the use of artificial intelligence in diagnosing neurological conditions. DISCLOSURES: Dr. Anup D Patel has been a consultant for Greenwich Biosciences, UCB Pharma, LivaNova, and Supernus. Dr. Patel’s other activities include Greenwich Biosciences, UCB Pharma, LivaNova, and Supernus. Dr. Patel’s has received research support for commercial entities from Greenwich Biosciences Brain Sentinel Upsher Smith Pharmaceuticals LivaNova, and research support from foundations and societies from Pediatric Epilepsy Research Foundation (PERF) American Academy of Neurology (AAN). Dr. Patel’s non-financial disclosures include serving on a voluntary basis as the vice chair for the AAN Quality Safety Subcommittee and as the chair for the Epilepsy Quality Measure work group.Dr. Andy Southerland has served on editorial boards for Journal Neurology, Section Editor Neurology Podcast Patents Intellectual property unrelated to current work: U.S. Patent Application No. 14/910,890 (iTREAT study) U.S. Provisional Patent Application No. 62/620,096 (BANDIT study). Dr. Southerland's consultancies include National Stroke Association - helped develop website for resources regarding telestroke and teleneurology, Research Support, Commercial Entities. Dr. Southerland's Edwards Lifesciences include perform neurological assessments for the PARTNER clinical trials of transcatheter aortic valve replacement. Dr. Southerland's Research Support, Government Entities include Stroke Hyperglycemia Insulin Network Effort (SHINE) NINDS/NIH U-01 NS 069498, Health Resources Services Administration - Evidence based tele-emergency network grant (RURAL EQUIT-E Project) HRSA G01RH27869, and NHLBI/NINDS - Cardiothoracic Surgical Trials Network (CTSN) - performed neurological assessments in conjunction with the neuroprotection trial of aortic valve replacement. Dr. Southerland's Research Support, Foundations and Societies include American Heart Association-American Stroke Association National Clinical Research Program, Cervical Artery Dissection Expression (CADEX) AHA 3CRP141400001, American Academy of Neurology - Education Research Grant, American Board of Psychiatry and Neurology - Faculty Fellowship Award. Dr. Southerland's legal proceedings include Legal Expert Review - perform expert review, on behalf of the UVA University Physician's Group, pertaining to stroke and vascular neurology questions for both plaintiff and defense cases.Dr. Eric Karl Oermann has received research support for foundations and societies from Doris Duke Charitable Research Foundation.

The American Academy of Neurology (AAN) is holding its Annual Meeting this week in Los Angeles. And with more than 10,000 neurologists all in one place, we're talking about a LOT of news coming out of that conference.   Just some of the topics we're talking about on this week's podcast: The AAN announced new guidelines for treating MS. A new study will convince you to begin MS disease-modifying therapy sooner, rather than later. The National MS Society has announced $14.2 million dollars in funding for 45 new research projects aimed at slowing, stopping, and ending MS. Genentech announced some good news for MS patients taking Ocrevus. Biogen announced the results of several MS research studies. Computer-based cognitive training can improve memory for people living with MS. My guest on the podcast is 3-time Stanley Cup winner and and star of the National Hockey League's Chicago Blackhawks, Bryan Bickell. Bryan retired from hockey last year, after being diagnosed with MS. We'll talk with Bryan about what it was like to get that diagnosis, what it was like to score that very memorable final goal of his career, and what lies ahead for him. (NOTE: During our conversation, Bryan references a website, "My Fighting Hockey Story". The correct website is MyFightingStory.com. Sorry for the confusion!) ____________ AAN Announces New Treatment Guidelines For MS  2:02 Study Indicates Importance of Starting MS Treatment ASAP  4:01 National MS Society Investing $14.2 Million in New Research  6:54 Genentech Has Good News For MS Patients Taking Ocrevus  8:25 Biogen Study Correlates MS Cognitive Decline to Socioeconomic Demographics  10:35 Computer-Based Cognitive Training Improves Memory for People Living with MS  12:49 The MSUnderstood Cafe Gives People A Taste of MS  13:49 Interview with hockey star Bryan Bickell  16:03 ___________ LINKSIf your podcast app doesn’t show these links, you’ll find them in the show notes at www.RealTalkMS.com American Academy of Neurology Annual Meeting   AAN Announces New Treatment Guidelines for MS   Early Versus Later Treatment Start in Multiple Sclerosis - A Register Based Cohort Study   Register for Interim Analysis of the Ocrelizumab Biomarker Outcome Evaluation Study in Multiple Sclerosis Research Study   Benchmarks of Cognitive Performance in a Large, Representative Patient Population   Cognitive Training and Neuropsychological Performance of Patients with Multiple Sclerosis   The MSUnderstood Cafe   Bryan Bickell's Career Final Shot is a Shootout Goal   Bryan Bickell's Story ___________ Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 29 Guest: Bryan Bickell Hosted By: Jon Strum Tags: MS, multiple sclerosis, AAN, AANAM, MS Treatment Guidelines, Genentech, Biogen, Ocrevus, NMSS, National MS Society, Roche, MSUnderstood Cafe, Bryan Bickell, RealTalkMS

1) Featured Article: Quality improvement in neurology: Child neurology quality measure set2) Lesson of the Week: Update on chronic migraine risk factors, management, and treatmentThis Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the January 9, 2018, issue of Neurology. In the first segment, Dr. Adam Numis talks with Dr. Jeffrey Buchhalter and Dr. Anup Patel about their quality measure set executive summary article regarding child neurology. For the “Lesson of the Week” segment, Dr. Tesha Monteith speaks with Dr. Stephen Silberstein about chronic migraine.DISCLOSURES:Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section; has received speaker honorarium from LivaNova; and has received research support from American Academy of Neurology, Clinical Research Training Fellowship in Epilepsy, 2017-2019, and American Epilepsy Society, Research and Training Fellowships for Clinicians, 2017-2018.Dr. Bucchalter has served on advisory and safety monitoring boards for NIH, NINDS, Observational Safety Monitoring Board for NIH, and the Charlie Foundation; has received travel and speaker honoraria from AAN, Eisai Co. Ltd., Child Neurology Society, Lundbeck, and Upsher-Smith Labs; serves on the editorial board for Pediatric Neurology; has consulted in the past with Lundbeck Inc., Eisai Co. Ltd., UCB, and Upsher-Smith; and has received research support from Alberta Health Services.Dr. Patel has served on scientific advisory board for UCB Pharma; has served as book and associate editor for Journal of Child Neurology; has consulted for Greenwich Biosciences, LivaNova, and Supernus; and has received research support from Greenwich Biosciences, Brain Sentinel, Upsher Smith Pharmaceuticals, LivaNova, Pediatric Epilepsy Research Foundation (PERF), and American Academy of Neurology (AAN).Dr. Silberstein has served on scientific advisory boards for Alder, Allergan, Amgen, Avanir, eNeura, ElectroCore Medical, Medscape, Medtronic, Mitsubishi Tanabe, Neuralieve, NINDS, Pfizer, Supernus, Teva, Curelator, Depomed, Dr. Reddy's Laboratories, Lilly, and Trigemina; has served on editorial boards for Cephalalgia, Current Pain and Headache Reports, CNS Drugs, Topics in Pain Management, and Neurology; has consulted for Allergan, Amgen, eNeura, ElectroCore Medical, Mitsubishi Tanabe, Medtronic, Neuralieve, Pfizer, Supernus, and Teva; served on speaker's bureaus in the past for Allergan, Endo Pharmaceuticals, GlaxoSmithKline, Zogenix, and Merck; and has received research support from GlaxoSmithKline, Allergan, Merck, Novartis, NIH, Neurolieve, MAP, Endo, Amgen, ElectroCore, Avanir, NIH, AHS, and IHS.Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH.

Why You Should Listen: In this episode, you will learn about autoimmunity and neurology in the context of Lyme disease and co-infections. About My Guest: My guest for this episode is Dr. Elena Frid, MD. Dr. Elena Frid is a Board Certified Neurologist and Clinical Neurophysiologist, widely regarded as a investigating diagnostician, adviser and treatment strategist specializing in Infection-Induced Autoimmune Disorders. Pioneering the field of Autoimmune Neurology, she often sees patients with complex cases of Lyme disease and co-infections resulting in multiple neurological complaints. Using cutting edge diagnostic tools and clinical expertise she is able to differentiate between idiopathic vs organic causes of various neurological disorders. Dr. Frid attended a coveted BA/MD program at Robert Wood Johnson Medical School and went on to North Shore-LIJ Health Care Systems where she completed residency in Neurology and fellowship in Clinical Neurophysiology (EMG / EEG). Her many areas of expertise are: General Neurology, Headaches & Migraines, Autoimmune Neurology, Neuropsychiatric and Neurodegenerative Disorders. Her knowledge has been sought by patients from all over the United States, as well as England, Germany, Spain, Australia, and Canada. She is one of the most experienced and unique Lyme doctors in the field, due to her background in Autoimmune Neurology, with heavy focus on diagnostic methodology, clinical expertise in neurology and psychiatry, and treatment therapy encompassing western and eastern medicine. Dr. Frid is a member of the American Academy of Neurology (AAN). She is a voting member of the International Lyme and Associated Diseases Society (ILADS), Medical Adviser to the Project Lyme organization, and member of the Independent Physicians of New York (IDNY). Upon request from families, Dr. Frid frequently collaborates on complex pediatric cases of Neuro Lyme disease with Dr. Charles Ray Jones, a world leading pediatric Lyme disease specialist with over 40 years’ experience in dealing with children with Lyme disease and other tick-borne illnesses. Key Takeaways: - How often is chronic Lyme neuro-Lyme? - What triggers autoimmunity? - Can autoimmune lab indicators be reversed? - What drives Hashimoto's? - How do you calm an over-active immune system? - What are the underlying issues in Chronic Fatigue, Fibromyalgia, MS, Parkinson's, ALS, and Alzheimer's? - What is PANDAS and PANS and does it resolve with treatment? - How do we keep our brains working well? - How can we heal the nerves after years of assault from chronic infections? - How can we reduce inflammation? - What causes seizures? Tinnitus? - What can we do about fear and anxiety involved in dealing with Lyme? Connect With My Guest: http://www.elenafridmd.com Interview Date: July 7, 2017 Disclaimer: The content of this show is for informational purposes only and is not intended to diagnose, treat, or cure any illness or medical condition. Nothing in today's discussion is meant to serve as medical advice or as information to facilitate self-treatment. As always, please discuss any potential health-related decisions with your own personal medical authority.

PRE-RECORDED -- MONDAY, September 17, 2012 In direct response to a previous show with Dr. LaVonne Goodman and information disseminated about the AAN (the American Academy of Neurology) Guidelines for Treating Chorea in Huntington's, (see report) Melissa Armstrong, MD, MSc and Gary Gronseth, MD, FAAN are here today to explain how the AAN Clinical Practice Guideline process works to deliver the best evidence-based recommendations to physicians who are treating for neurological disorders, in particular chorea in Huntington's disease. For more information about the American Academy of Neurology, visit www.aan.com.   We are honored, delighted and thrilled to have the prestigious American Academy of Neurology here with us today… About the AAN The American Academy of Neurology (AAN), established in 1948, is an international professional association of more than 25,000 neurologists and neuroscience professionals dedicated to promoting the highest quality patient-centered neurologic care.  

Wednesday, August 8, 2012 In direct response to previous shows and information disseminated about the AAN (the American Academy of Neurology) guidelines for treating chorea in Huntington's, Melissa Armstrong, MD, MSc and Gary Gronseth, MD, FAAN are here today to explain how the AAN Clinical Practice Guideline process works to deliver the best evidence-based recommendations to physicians who are treating for neurological disorders, in particular Huntington's disease.  About the AAN The American Academy of Neurology (AAN), established in 1948, is an international professional association of more than 25,000 neurologists and neuroscience professionals dedicated to promoting the highest quality patient-centered neurologic care. Gary S Gronseth, MD, FAAN Dr. Gronseth is a Professor of Neurology at the University of Kansas and has been involved with patient care and medical education for 25 years. Dr Gronseth is also the evidence-based medicine (EBM) methodologist for the American Academy of Neurology (AAN). He oversees many EBM projects of the AAN including the development of clinical practice guidelines for 18 years. Melissa J Armstrong, MD, MSc Dr. Armstrong is an Assistant Professor of Neurology at the University of Maryland School of Medicine is fellowship-trained in movement disorders and has a master's degree in health care research from the University of Toronto. She cares for patients at the University of Maryland Parkinson's Disease and Movement Disorders Center, participates in medical research and has been involved in guideline development for the American Academy of Neurology (AAN) since 2006, first as an author and now also as a member of the Guideline Development Subcommittee. www.aan.com